No Carolina / NY / Florida
Ph: 561.316.3330

Adaptive Phage Therapeutics Closes on $12 Million Investment in $30 Million Series B1 to Fight Antibiotic Resistant Infections

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, announced today that it has received a $12 million upfront investment from funds managed by Deerfield Management and the AMR Action Fund as part of a new $24 million total investment in a Series B1 round that is targeting $30 million in aggregate.
  • “APT has the potential to make a significant impact in the fight against antibiotic resistance, and I look forward to working with the team to make these therapies broadly available to patients.
  • Concurrent with the investment, APT is expanding its Board of Directors to include Ian Hardy, PhD, MBA, Vice President of Chemistry, Manufacturing and Controls (CMC), Deerfield Discovery and Development at Deerfield Management.

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, announced today that it has received a $12 million upfront investment from funds managed by Deerfield Management and the AMR Action Fund as part of a new $24 million total investment in a Series B1 round that is targeting $30 million in aggregate.

Antimicrobial resistance (AMR) is a growing public health concern, and this investment enables continuing clinical progression of APT’s pipeline of phage therapies to combat AMR infections. APT’s platform utilizes bacteriophages, or viruses that specifically target and kill bacteria, to create personalized treatments for patients with difficult-to-treat infections.

“We are thrilled to have the ongoing support of Deerfield and the AMR Action Fund as we work to address the urgent need for new treatments to combat antibiotic resistance,” said Greg Merril, co-Founder and CEO of APT. “This investment will allow us to advance our lead clinical programs related to musculoskeletal infections, including prosthetic joint infections and diabetic foot osteomyelitis.”

Concurrent with the investment, APT is expanding its Board of Directors to include Ian Hardy, PhD, MBA, Vice President of Chemistry, Manufacturing and Controls (CMC), Deerfield Discovery and Development at Deerfield Management. Dr. Hardy will serve as APT’s Board Chair. With over 30 years of experience in large pharmaceutical and biotech companies, covering a broad range of development programs from discovery through commercialization, Dr. Hardy brings a wealth of expertise to the APT team.

“I am excited to join the Board of Directors at APT and help advance their innovative phage therapy platform,” said Ian Hardy. “APT has the potential to make a significant impact in the fight against antibiotic resistance, and I look forward to working with the team to make these therapies broadly available to patients.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Abu Dhabi Issues First BioTech Inventor-Class Golden Visa to Catalyze “Made-In-Abu-Dhabi IP” to Rockefeller University Inventor Dr Kambiz Shekdar, PhD

Dr Kambiz Shekdar said: "I gratefully take this opportunity as my solemn commitment to help build up the BioTech sector in Abu Dhabi with the same home-grown can-do-and-have-done record of accomplishment demonstrated by Emirati leadership, its people, and nation, and to do so collegially with the best of the best of the world's human capital across frontier technologies who, like myself, are drawn to the UAE with the thirst to pioneer and build better like only possible in the red-hot entrepreneurial climate of the UAE."

Activation Capital Introduces ‘Frontier BioHealth’ to Catalyze Life Science Startups

"We celebrate the growing base of research and technological advances within the region's health and life sciences sector," said Chandra Briggman, President and CEO of Activation Capital.

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models

By using this website you agree to accept Medical Device News Magazine Privacy Policy